Sruthi S. Nair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sruthi S. Nair has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Soumya Sundaram
Sree Chitra Tirunal Institute for Medical Sciences and Technology
10 shared publications Muralidharan Nair
Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India
7 shared publications- Asish Vijayaraghavan
Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India
3 shared publications - Bejoy Thomas
Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India
3 shared publications Chandrasekharan Kesavadas
Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India
3 shared publicationsElshal Bava
Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India
3 shared publications
Latest Publications
- 26 October 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Perivascular Diffusivity and Periventricular Susceptibility Changes in Relapsing–Remitting Multiple Sclerosis: A Combined DTI ‐ ALPS and QSM Study
Background: Progressive periventricular damage in multiple sclerosis (MS) has been linked to impaired perivascular clearance and to susceptibility changes attributed to iron deposition and myelin loss. Their relationship is unclear. Purpose/Hypothesis: To compare diffusion tensor image analysis along the perivascular space (DTI‐ALPS) and periventricular quantitative susceptibility mapping (QSM) between relapsing–remitting multiple sclerosis (RRMS) patients and healthy controls; and to evaluate their correlation and relationships with clinical disability (Expanded Disability Status Scale, EDSS). Study Type: Retrospective case–control study. Population/Subjects: Thirty one patients with RRMS (mean age, 34.6 ± 8.4 years) and 30 age‐ and sex‐matched healthy controls (mean age, 34.2 ± 8.1 years). Field Strength/Sequence: 1.5 T; Diffusion tensor imaging (DTI) and multi‐echo gradient‐echo (GRE) sequences. Assessment: DTI‐ALPS index and periventricular QSM values were measured from manually placed bilateral regions of interest (ROIs). Standardized Montreal Neurological Institute (MNI)‐space coordinates were used for DTI‐ALPS analysis, and QSM ROIs in periventricular normal‐appearing white matter were reviewed by a neuroradiologist. Disability was assessed using the EDSS. Statistical Tests: Groups were compared using independent‐samples t ‐tests and Cohen's d. Correlations were assessed using Pearson's r, with Spearman's rho as a sensitivity analysis ( p < 0.05, two‐tailed). Results: DTI‐ALPS was lower in MS patients than controls (1.27 ± 0.22 vs. 1.45 ± 0.22; d = 0.828), whereas periventricular QSM was higher (−15.35 ± 4.92 vs. −21.70 ± 6.40 ppb; d = 1.116). A strong negative correlation between the two biomarkers was observed across all subjects ( r = −0.738). Both measures correlated with EDSS (DTI‐ALPS r = −0.509; QSM r = 0.501) and differed between EDSS subgroups (EDSS > 2.0 vs. ≤ 2.0: DTI‐ALPS 1.160 vs. 1.364; QSM −12.33 vs. −17.83 ppb). Data Conclusion: Reduced DTI‐ALPS and higher periventricular QSM‐derived susceptibility were each moderately associated with disability in RRMS. The negative DTI‐ALPS–QSM correlation in both groups indicates an association between perivascular diffusivity, a putative marker of glymphatic function, and periventricular QSM‐derived susceptibility; causality cannot be established from this cross‐sectional design. Level of Evidence: 3. Stage of Technical Efficacy: 2.
- 26 October 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Perivascular Diffusivity and Periventricular Susceptibility Changes in Relapsing–Remitting Multiple Sclerosis: A Combined DTI ‐ ALPS and QSM Study
Background: Progressive periventricular damage in multiple sclerosis (MS) has been linked to impaired perivascular clearance and to susceptibility changes attributed to iron deposition and myelin loss. Their relationship is unclear. Purpose/Hypothesis: To compare diffusion tensor image analysis along the perivascular space (DTI‐ALPS) and periventricular quantitative susceptibility mapping (QSM) between relapsing–remitting multiple sclerosis (RRMS) patients and healthy controls; and to evaluate their correlation and relationships with clinical disability (Expanded Disability Status Scale, EDSS). Study Type: Retrospective case–control study. Population/Subjects: Thirty one patients with RRMS (mean age, 34.6 ± 8.4 years) and 30 age‐ and sex‐matched healthy controls (mean age, 34.2 ± 8.1 years). Field Strength/Sequence: 1.5 T; Diffusion tensor imaging (DTI) and multi‐echo gradient‐echo (GRE) sequences. Assessment: DTI‐ALPS index and periventricular QSM values were measured from manually placed bilateral regions of interest (ROIs). Standardized Montreal Neurological Institute (MNI)‐space coordinates were used for DTI‐ALPS analysis, and QSM ROIs in periventricular normal‐appearing white matter were reviewed by a neuroradiologist. Disability was assessed using the EDSS. Statistical Tests: Groups were compared using independent‐samples t ‐tests and Cohen's d. Correlations were assessed using Pearson's r, with Spearman's rho as a sensitivity analysis ( p < 0.05, two‐tailed). Results: DTI‐ALPS was lower in MS patients than controls (1.27 ± 0.22 vs. 1.45 ± 0.22; d = 0.828), whereas periventricular QSM was higher (−15.35 ± 4.92 vs. −21.70 ± 6.40 ppb; d = 1.116). A strong negative correlation between the two biomarkers was observed across all subjects ( r = −0.738). Both measures correlated with EDSS (DTI‐ALPS r = −0.509; QSM r = 0.501) and differed between EDSS subgroups (EDSS > 2.0 vs. ≤ 2.0: DTI‐ALPS 1.160 vs. 1.364; QSM −12.33 vs. −17.83 ppb). Data Conclusion: Reduced DTI‐ALPS and higher periventricular QSM‐derived susceptibility were each moderately associated with disability in RRMS. The negative DTI‐ALPS–QSM correlation in both groups indicates an association between perivascular diffusivity, a putative marker of glymphatic function, and periventricular QSM‐derived susceptibility; causality cannot be established from this cross‐sectional design. Level of Evidence: 3. Stage of Technical Efficacy: 2.
- Open Access
- 10 April 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 48, 100762
Patient profiles and disease characteristics in the Indian Multiple Sclerosis and allied demyelinating disorders registry and research network (IMSRN) Cohort: a multicentre study (2021–2025)
- 10 April 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 48, 100762
Open AccessPatient profiles and disease characteristics in the Indian Multiple Sclerosis and allied demyelinating disorders registry and research network (IMSRN) Cohort: a multicentre study (2021–2025)
- 10 June 2025
- Published by Springer Nature in The Cerebellum
- Vol. 24 (4) , 1-7
Phenotypic Diversity in Stress-induced Childhood-Onset Neurodegeneration with Variable Ataxia and Seizures: Novel Associations with Parkinsonism, Icthyosis and Cataract
Stress-induced childhood-onset neurodegeneration with variable ataxia and seizures (CONDSIAS) is an exceptionally rare autosomal recessive neurodegenerative disorder. It is caused by biallelic inactivating variants in the ADP-ribosyl-serine hydrolase (ADPRS) gene that encodes for the enzyme ADP-ribosyl hydrolase3 (ARH3) involved in DNA repair. A distinctive feature of this condition is the exacerbation of clinical symptoms triggered by physical or emotional stress, as well as febrile illnesses. In this report, we describe three unrelated patients diagnosed with CONDSIAS, each having variable clinical phenotypes and responses to treatment. Patient 1 is a 26-year-old female with language delay, intellectual disability, and infrequent seizures in childhood. She later developed parkinsonism, truncal dystonia, ataxia, peripheral neuropathy, and neuropsychiatric symptoms in her second decade. Patient 2, an 8-year-old boy born to consanguineous parents, presented with infection-triggered episodic ataxia and ichthyosis. His elder sibling had suffered from progressive ataxia and succumbed to sudden death at the age of 8. Patient 3 is a 6-year-old girl who presented with progressive ataxia, myoclonus, oculomotor apraxia, and upward gaze palsy. Both patients 2 and 3 responded favourably to treatment with high-dose vitamin supplementation, while patient 1 showed stable disease progression without specific therapeutic intervention, suggesting spontaneous stabilization of her condition. Extra-neurological manifestations included ichthyosis in patients 1 and 2 and cataracts in patient 1. These three cases illustrate the heterogeneity in clinical presentation and prognosis of CONDSIAS, highlighting the occurrence of predominant extrapyramidal features and systemic involvement, thereby expanding the phenotypic spectrum beyond the typical manifestations of ataxia and seizures.
- 10 June 2025
- Published by Springer Nature in The Cerebellum
- Vol. 24 (4) , 1-7
Phenotypic Diversity in Stress-induced Childhood-Onset Neurodegeneration with Variable Ataxia and Seizures: Novel Associations with Parkinsonism, Icthyosis and Cataract
Stress-induced childhood-onset neurodegeneration with variable ataxia and seizures (CONDSIAS) is an exceptionally rare autosomal recessive neurodegenerative disorder. It is caused by biallelic inactivating variants in the ADP-ribosyl-serine hydrolase (ADPRS) gene that encodes for the enzyme ADP-ribosyl hydrolase3 (ARH3) involved in DNA repair. A distinctive feature of this condition is the exacerbation of clinical symptoms triggered by physical or emotional stress, as well as febrile illnesses. In this report, we describe three unrelated patients diagnosed with CONDSIAS, each having variable clinical phenotypes and responses to treatment. Patient 1 is a 26-year-old female with language delay, intellectual disability, and infrequent seizures in childhood. She later developed parkinsonism, truncal dystonia, ataxia, peripheral neuropathy, and neuropsychiatric symptoms in her second decade. Patient 2, an 8-year-old boy born to consanguineous parents, presented with infection-triggered episodic ataxia and ichthyosis. His elder sibling had suffered from progressive ataxia and succumbed to sudden death at the age of 8. Patient 3 is a 6-year-old girl who presented with progressive ataxia, myoclonus, oculomotor apraxia, and upward gaze palsy. Both patients 2 and 3 responded favourably to treatment with high-dose vitamin supplementation, while patient 1 showed stable disease progression without specific therapeutic intervention, suggesting spontaneous stabilization of her condition. Extra-neurological manifestations included ichthyosis in patients 1 and 2 and cataracts in patient 1. These three cases illustrate the heterogeneity in clinical presentation and prognosis of CONDSIAS, highlighting the occurrence of predominant extrapyramidal features and systemic involvement, thereby expanding the phenotypic spectrum beyond the typical manifestations of ataxia and seizures.
- Open Access
- 30 May 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (3) , 363-370
A Clinical Study on the Utility of Muscle Biopsy in Patients with Suspected Myopathy
Background and Objectives: The role of muscle biopsy needs to be redefined in an era where genetic studies have largely supplanted the need for a pathological diagnosis. The objective of the study was to evaluate the utility of muscle biopsy in suspected myopathies in terms of diagnostic confirmation and modifying therapy in a developing country. Methods: We conducted a retrospective observational study of patients who underwent muscle biopsy in our center between April 2017 and 2019. The diagnostic utility and therapeutic impact of muscle biopsy were assessed descriptively and using an ordinal score. We further analyzed the correlation of the pathological diagnosis with the genetic and immunological data. Results: Among the 70 patients included in the study over a 2-year period, 33 (47.1%) were aged 18 years or less and the mean age was 23.4 (±16.2) years. A specific diagnosis or diagnostic category could be established in 39 (55.7%) of all patients and 21 (63.6%) among pediatric patients by muscle biopsy. The most common categories were muscular dystrophies in 27 (38.6%) patients and inflammatory myopathies in seven (10%) patients. Mitochondrial myopathy was confirmed in two (2.9%), while three (4.3%) had other specific diagnosis and 31 (44.2%) had indeterminate/normal biopsy reports. Muscle biopsy confirmed the pre-biopsy diagnosis in 29 (41.4%) patients and changed the clinical diagnosis in 16 (22.9%) patients. Category-wise, the change in pre-biopsy diagnosis was significant only in suspected mitochondrial myopathies, but not in other categories. Conclusions: Muscle biopsy helped in securing a specific diagnosis in approximately one-half of the patients. This study underscores the enduring relevance of muscle biopsy in settings where resources for advanced genetic testing and data analysis are constrained.
- 30 May 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (3) , 363-370
Open AccessA Clinical Study on the Utility of Muscle Biopsy in Patients with Suspected Myopathy
Background and Objectives: The role of muscle biopsy needs to be redefined in an era where genetic studies have largely supplanted the need for a pathological diagnosis. The objective of the study was to evaluate the utility of muscle biopsy in suspected myopathies in terms of diagnostic confirmation and modifying therapy in a developing country. Methods: We conducted a retrospective observational study of patients who underwent muscle biopsy in our center between April 2017 and 2019. The diagnostic utility and therapeutic impact of muscle biopsy were assessed descriptively and using an ordinal score. We further analyzed the correlation of the pathological diagnosis with the genetic and immunological data. Results: Among the 70 patients included in the study over a 2-year period, 33 (47.1%) were aged 18 years or less and the mean age was 23.4 (±16.2) years. A specific diagnosis or diagnostic category could be established in 39 (55.7%) of all patients and 21 (63.6%) among pediatric patients by muscle biopsy. The most common categories were muscular dystrophies in 27 (38.6%) patients and inflammatory myopathies in seven (10%) patients. Mitochondrial myopathy was confirmed in two (2.9%), while three (4.3%) had other specific diagnosis and 31 (44.2%) had indeterminate/normal biopsy reports. Muscle biopsy confirmed the pre-biopsy diagnosis in 29 (41.4%) patients and changed the clinical diagnosis in 16 (22.9%) patients. Category-wise, the change in pre-biopsy diagnosis was significant only in suspected mitochondrial myopathies, but not in other categories. Conclusions: Muscle biopsy helped in securing a specific diagnosis in approximately one-half of the patients. This study underscores the enduring relevance of muscle biopsy in settings where resources for advanced genetic testing and data analysis are constrained.
- Open Access
- 5 May 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 12 (4) , 513-522
Kennedy's disease from India: An Indian Cohort with multisystemic manifestations
Background: Kennedy's disease (KD) is a rare, insidiously progressive lower motor neuron syndrome characterised by amyotrophy involving the appendicular or bulbar musculature of adult males in their fourth to fifth decade. There are no large series from the Indian subcontinent describing the clinical-genetic and laboratory spectrum of KD. Aim: To describe the clinical, electrophysiologic, metabolic and genetic profile of patients with KD. Methods: We conducted a retrospective review of ten genetically confirmed KD patients. Results: The mean age of the cohort was 47 years, with a mean age of onset of illness at 41.3 ± 9.9 years. The median duration of symptoms before presentation was 5 (3–12) years. The most common referral diagnosis was ALS. The majority presented with symmetric proximal limb weakness with bulbar symptoms and were found to have gynecomastia, lower motor neuron (LMN) facial weakness, and facial and lingual fasciculations. Electrophysiology revealed sensory neuropathy in five patients and chronic neurogenic changes consistent with anterior horn cell disease in all. Metabolic profile showed impaired glycemia, hyperlipidemia and evidence of non-alcoholic fatty liver disease in the majority. All had elevated serum creatine kinase. Genetic testing revealed a median of 46 CAG repeats. The phenotypes of our patients aligned with global data that is predominantly derived from participants of European ancestry. Conclusion: We describe a series of patients with KD from India with significant multisystemic involvement.
- 5 May 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 12 (4) , 513-522
Open AccessKennedy's disease from India: An Indian Cohort with multisystemic manifestations
Background: Kennedy's disease (KD) is a rare, insidiously progressive lower motor neuron syndrome characterised by amyotrophy involving the appendicular or bulbar musculature of adult males in their fourth to fifth decade. There are no large series from the Indian subcontinent describing the clinical-genetic and laboratory spectrum of KD. Aim: To describe the clinical, electrophysiologic, metabolic and genetic profile of patients with KD. Methods: We conducted a retrospective review of ten genetically confirmed KD patients. Results: The mean age of the cohort was 47 years, with a mean age of onset of illness at 41.3 ± 9.9 years. The median duration of symptoms before presentation was 5 (3–12) years. The most common referral diagnosis was ALS. The majority presented with symmetric proximal limb weakness with bulbar symptoms and were found to have gynecomastia, lower motor neuron (LMN) facial weakness, and facial and lingual fasciculations. Electrophysiology revealed sensory neuropathy in five patients and chronic neurogenic changes consistent with anterior horn cell disease in all. Metabolic profile showed impaired glycemia, hyperlipidemia and evidence of non-alcoholic fatty liver disease in the majority. All had elevated serum creatine kinase. Genetic testing revealed a median of 46 CAG repeats. The phenotypes of our patients aligned with global data that is predominantly derived from participants of European ancestry. Conclusion: We describe a series of patients with KD from India with significant multisystemic involvement.
- Open Access
- 1 May 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (3) , 344-345
Optimizing Cardiac Assessment in Idiopathic Inflammatory Myopathies
- 1 May 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (3) , 344-345
Open AccessOptimizing Cardiac Assessment in Idiopathic Inflammatory Myopathies
- Open Access
- 1 November 2024
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 27 (6) , 706-709
Rituximab in Refractory Myasthenia Gravis – Challenges and Lessons Learnt
Nearly 10%–15% patients with generalized myasthenia gravis (MG) have refractory disease and are candidates for newer nonconventional immunotherapies. Rituximab has emerged as an attractive option in them. We describe the efficacy and safety of rituximab in 12 patients with refractory MG treated over a period of 4 years in a tertiary care center. We had a female-predominant cohort (10 females) in the age range 10–67 years. There were eight seropositive patients (acetylcholine receptor, muscle-specific kinase, or both antibodies) and eight had undergone thymectomy. Median number of crises was 2 before treatment with rituximab. Sustained improvement at 12 months was seen in seven patients and steroid dose could be reduced in them. Four worsened on therapy (including one death following prolonged ventilation and septicemia). One patient who had no response to therapy was re-evaluated and diagnosed with congenital myasthenic syndrome related to biallelic CHRNE mutation. In summary, nearly two-thirds (7/11, 63.6%) of autoimmune refractory MG in this cohort showed a good response to rituximab.
- 1 November 2024
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 27 (6) , 706-709
Open AccessRituximab in Refractory Myasthenia Gravis – Challenges and Lessons Learnt
Nearly 10%–15% patients with generalized myasthenia gravis (MG) have refractory disease and are candidates for newer nonconventional immunotherapies. Rituximab has emerged as an attractive option in them. We describe the efficacy and safety of rituximab in 12 patients with refractory MG treated over a period of 4 years in a tertiary care center. We had a female-predominant cohort (10 females) in the age range 10–67 years. There were eight seropositive patients (acetylcholine receptor, muscle-specific kinase, or both antibodies) and eight had undergone thymectomy. Median number of crises was 2 before treatment with rituximab. Sustained improvement at 12 months was seen in seven patients and steroid dose could be reduced in them. Four worsened on therapy (including one death following prolonged ventilation and septicemia). One patient who had no response to therapy was re-evaluated and diagnosed with congenital myasthenic syndrome related to biallelic CHRNE mutation. In summary, nearly two-thirds (7/11, 63.6%) of autoimmune refractory MG in this cohort showed a good response to rituximab.
- Open Access
- 1 October 2024
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 10 (4)
Mapping cognitive dysfunction in relapsing multiple sclerosis with mild disability: A cross-sectional study from South India
Background: Cognitive dysfunction in multiple sclerosis (MS) occurs early. Locally adapted neuropsychological data from India in MS is scarce. Objectives: We aimed to identify the pattern of cognitive impairment in relapsing MS (RMS) with mild disability using a regionally-adapted MS-specific cognitive battery. Methodology: The study included 59 persons with MS (pwMS) with expanded disability status scale (EDSS)≤ 4 and 62 controls. The battery had 8 neuropsychological tests (Paced Auditory Serial Addition Test [PASAT], Symbol Digit Modalities Test [SDMT], Rey Auditory Verbal Learning Test [RAVLT], Brief Visuospatial Memory Test-Revised [BVMT-R], verbal fluency [VF], Judgement of Line Orientation Test [JOLOT], Wisconsin Card Sorting Test [WCST] and Trail Making Test-B [TMT-B]) with 11 measures. The scores were compared between the groups for pattern and associations of cognitive impairment. Results: The pwMS cohort had 39 (66.1%) females; mean age of 32.56 (±8.17) years. Scores were significantly worse for pwMS in 10 of 11 tests (except JOLOT). Cohen's-d test showed the largest effect sizes for PASAT, SDMT, VF and TMT-B. Cognitive impairment (defined as ≥2 abnormal tests) were noted in 41 (69.5%) pwMS. Male sex was associated with cognitive impairment ( p = 0.002). Conclusions: In pwMS with mild disability, nearly two-thirds had cognitive abnormalities, predominantly involving processing speed, working memory, executive function, and VF.
- 1 October 2024
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 10 (4)
Open AccessMapping cognitive dysfunction in relapsing multiple sclerosis with mild disability: A cross-sectional study from South India
Background: Cognitive dysfunction in multiple sclerosis (MS) occurs early. Locally adapted neuropsychological data from India in MS is scarce. Objectives: We aimed to identify the pattern of cognitive impairment in relapsing MS (RMS) with mild disability using a regionally-adapted MS-specific cognitive battery. Methodology: The study included 59 persons with MS (pwMS) with expanded disability status scale (EDSS)≤ 4 and 62 controls. The battery had 8 neuropsychological tests (Paced Auditory Serial Addition Test [PASAT], Symbol Digit Modalities Test [SDMT], Rey Auditory Verbal Learning Test [RAVLT], Brief Visuospatial Memory Test-Revised [BVMT-R], verbal fluency [VF], Judgement of Line Orientation Test [JOLOT], Wisconsin Card Sorting Test [WCST] and Trail Making Test-B [TMT-B]) with 11 measures. The scores were compared between the groups for pattern and associations of cognitive impairment. Results: The pwMS cohort had 39 (66.1%) females; mean age of 32.56 (±8.17) years. Scores were significantly worse for pwMS in 10 of 11 tests (except JOLOT). Cohen's-d test showed the largest effect sizes for PASAT, SDMT, VF and TMT-B. Cognitive impairment (defined as ≥2 abnormal tests) were noted in 41 (69.5%) pwMS. Male sex was associated with cognitive impairment ( p = 0.002). Conclusions: In pwMS with mild disability, nearly two-thirds had cognitive abnormalities, predominantly involving processing speed, working memory, executive function, and VF.